{"title":"通过z分数对标非劣效性设计和分析。","authors":"Jin Wang","doi":"10.1007/s00228-025-03877-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Non-inferiority (NI) design and analyses are frequently employed to provide alternative therapy options to patients, ensuring these therapies are not significantly worse in terms of safety and effectiveness compared to the standard therapy. However, unlike superiority analysis, non-inferiority analysis faces the inherent challenge of a potentially irrelevant NI margin. It is not uncommon for the observed control performance to differ significantly from the assumed one, which can render the NI margin irrelevant. The purpose of this paper is to utilize Z-score to investigate this issue.</p><p><strong>Methods: </strong>This paper proposes using the Z-score to evaluate the NI design and connect the NI design and analysis. This approach provides a benchmark tool that even when actual outcomes differ significantly from assumptions, the NI margin can be moderated to balance clinical relevance and statistical practicality.</p><p><strong>Results: </strong>Illustrative calibrations and case studies demonstrate the feasibility of this approach, facilitating the transition from NI design to analysis.</p><p><strong>Conclusion: </strong>The Z-score can be used to assess the quality of the NI design and serve as a bridge between NI design and analysis.</p>","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":"1421-1427"},"PeriodicalIF":2.7000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Benchmarking non-inferiority design and analysis through the Z-score.\",\"authors\":\"Jin Wang\",\"doi\":\"10.1007/s00228-025-03877-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Non-inferiority (NI) design and analyses are frequently employed to provide alternative therapy options to patients, ensuring these therapies are not significantly worse in terms of safety and effectiveness compared to the standard therapy. However, unlike superiority analysis, non-inferiority analysis faces the inherent challenge of a potentially irrelevant NI margin. It is not uncommon for the observed control performance to differ significantly from the assumed one, which can render the NI margin irrelevant. The purpose of this paper is to utilize Z-score to investigate this issue.</p><p><strong>Methods: </strong>This paper proposes using the Z-score to evaluate the NI design and connect the NI design and analysis. This approach provides a benchmark tool that even when actual outcomes differ significantly from assumptions, the NI margin can be moderated to balance clinical relevance and statistical practicality.</p><p><strong>Results: </strong>Illustrative calibrations and case studies demonstrate the feasibility of this approach, facilitating the transition from NI design to analysis.</p><p><strong>Conclusion: </strong>The Z-score can be used to assess the quality of the NI design and serve as a bridge between NI design and analysis.</p>\",\"PeriodicalId\":11857,\"journal\":{\"name\":\"European Journal of Clinical Pharmacology\",\"volume\":\" \",\"pages\":\"1421-1427\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Clinical Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00228-025-03877-9\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00228-025-03877-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Benchmarking non-inferiority design and analysis through the Z-score.
Purpose: Non-inferiority (NI) design and analyses are frequently employed to provide alternative therapy options to patients, ensuring these therapies are not significantly worse in terms of safety and effectiveness compared to the standard therapy. However, unlike superiority analysis, non-inferiority analysis faces the inherent challenge of a potentially irrelevant NI margin. It is not uncommon for the observed control performance to differ significantly from the assumed one, which can render the NI margin irrelevant. The purpose of this paper is to utilize Z-score to investigate this issue.
Methods: This paper proposes using the Z-score to evaluate the NI design and connect the NI design and analysis. This approach provides a benchmark tool that even when actual outcomes differ significantly from assumptions, the NI margin can be moderated to balance clinical relevance and statistical practicality.
Results: Illustrative calibrations and case studies demonstrate the feasibility of this approach, facilitating the transition from NI design to analysis.
Conclusion: The Z-score can be used to assess the quality of the NI design and serve as a bridge between NI design and analysis.
期刊介绍:
The European Journal of Clinical Pharmacology publishes original papers on all aspects of clinical pharmacology and drug therapy in humans. Manuscripts are welcomed on the following topics: therapeutic trials, pharmacokinetics/pharmacodynamics, pharmacogenetics, drug metabolism, adverse drug reactions, drug interactions, all aspects of drug development, development relating to teaching in clinical pharmacology, pharmacoepidemiology, and matters relating to the rational prescribing and safe use of drugs. Methodological contributions relevant to these topics are also welcomed.
Data from animal experiments are accepted only in the context of original data in man reported in the same paper. EJCP will only consider manuscripts describing the frequency of allelic variants in different populations if this information is linked to functional data or new interesting variants. Highly relevant differences in frequency with a major impact in drug therapy for the respective population may be submitted as a letter to the editor.
Straightforward phase I pharmacokinetic or pharmacodynamic studies as parts of new drug development will only be considered for publication if the paper involves
-a compound that is interesting and new in some basic or fundamental way, or
-methods that are original in some basic sense, or
-a highly unexpected outcome, or
-conclusions that are scientifically novel in some basic or fundamental sense.